Objective To investigate the clinical effect of Monosialteterahexosyl ganglioside in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity(CIPN)in patients with non-small cell lung cancer(NSCLC)during albu-min-binding paclitaxel chemotherapy.Methods A total of 80 patients with NSCLC admitted to the Oncology Department of Jiangxi Chest Hospital from February 2020 to October 2022 were selected.Random number table method was used for con-trol observation.The control group(Albumin-binding Paclitaxel chemotherapy)and the treatment group(Albumin-binding Paclitaxel chemotherapy combined with intravenous injection of Monosialteterahexosyl ganglioside)included 40 patients each.CIPN incidence,clinical symptom remission time,interleukin-6(IL-6),cortisol(Cor),C-reactive protein(CRP)and adverse reactions were compared.Results The incidence of CIPN in the treatment group was lower than that in the control group,with a statistically significant difference(P＜0.05).The relief time of symptoms such as limb numbness,limb pain,and hand foot sensation in the treatment group was shorter than that in the control group,with a statistically significant dif-ference(P＜0.05).After treatment,the levels of IL-6,Cor,and CRP in both groups were lower than before treatment,and the treatment group was lower than the control group,with statistical significances(P＜0.05).There was no statistically sig-nificant difference in adverse reactions such as rash,liver and kidney damage,and abnormal heartbeat between the two groups(P＞0.05).Conclusion Intravenous injection of Monosialteterahexosyl ganglioside during the treatment of non-small cell lung cancer patients with albumin-binding paclitaxel chemotherapy can effectively prevent peripheral neurotoxicity,re-lieve clinical symptoms,reduce inflammatory stress state,safe and has clinical application value.
维普
万方数据